Market News & Trends
Aytu BioScience Receives Market Approval for the MiOXSYS System for Male Infertility
Aytu BioScience, Inc. recently announced that the Australian Government Department of Health and Therapeutic Goods Administration (TGA) has approved the MiOXSYS System for inclusion on…
BriaCell Provides Clinical Update on its Lead Vaccine Candidate
BriaCell Therapeutics Corp. recently released a clinical update on its ongoing Phase I/IIa study of its lead vaccine candidate, BriaVax, in advanced breast cancer patients.…
Citoxlab Acquires American CRO Xenometrics
Citoxlab Group recently announced the acquisition of Xenometrics, an American CRO specialized in the non-clinical assessment of new drug candidates. This acquisition is the third…
Sarepta Therapeutics Signs Exclusive Global Collaboration
Sarepta Therapeutics, Inc. recently announced it has signed a research collaboration agreement with Duke University, granting the company an option to an exclusive license to…
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. recently announced the presentation of preliminary data from an ongoing Phase 2 proof-of-concept study evaluating the safety and efficacy of setmelanotide, the…
Novoteris Investigator Receives Health Canada Clearance to Start Phase 2a Clinical Trial
Novoteris, LLC recently announced that the Therapeutic Products Directorate of Health Canada has cleared an investigator sponsored, pilot clinical trial application exploring the treatment of…
Arcturus Therapeutics & Synthetic Genomics Announce Strategic Alliance
Arcturus Therapeutics, Inc. and Synthetic Genomics, Inc. recently announced they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines…
Catalent Collaborates With Grid Therapeutics to Develop Novel Targeted Immuno-Oncology Therapy
Catalent Pharma Solutions recently announced it has signed a multi-year agreement with Grid Therapeutics, LLC, for the development and manufacture of Grid’s lead therapeutic candidate…
AC Immune SA to Receive Milestone Payment
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, recently announced that Genentech, a member…
Evonik & Eli Lilly Announce Renewal of a Long-Term Agreement
Evonik Industries and Eli Lilly and Company (Lilly) today announced the renewal of a long-term agreement under which Evonik will supply active pharmaceutical ingredients (APIs)…
Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study
Molecular Templates, Inc. recently announced the dosing of the first patient in a Phase 1 expansion study of MT-3724, a first-generation ETB that targets the…
Cognition Therapeutics Announces Issuance of Patent for a First-in-Class Alzheimer’s Disease Clinical Candidate
Cognition Therapeutics, Inc. recently announced the USPTO has issued a composition of matter patent for a family of novel compounds including CT1812, Cognition’s first-in-class, orally…
Catalyst Biosciences & Mosaic Biosciences Enter Strategic Development Collaboration
Catalyst Biosciences, Inc. and privately held Mosaic Biosciences, Inc. recently announced they have entered into a strategic collaboration to develop Catalyst’s anti-C3 protease assets for…
Bracket Acquires mProve Health to Radically Advance Patient Engagement in Clinical Trials
Bracket recently announced the strategic acquisition of mProve Health Inc. (mProve), a leading provider of mobile technologies for life science companies. The acquisition centers on…
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial
Sienna Biopharmaceuticals, Inc. recently announced the first patient has been dosed in the Company’s Phase 2b clinical trial of topical product candidate SNA-120 (pegcantratinib) in…
Aclaris Therapeutics Announces the Allowance of a US Patent Application & Issuance Covering Hair Loss Disorders
Aclaris Therapeutics, Inc. recently announced that Columbia University has received a Notice of Allowance from the USPTO for a patent application covering methods of treating…
Genisphere Pursues Neurotherapeutics Under Collaboration Agreement With Inserm
Genisphere LLC has signed a collaborative research agreement with The Institut national de la santé et de la recherche médicale (Inserm, The French National Institute…
Cognition Therapeutics Receives Fast Track Designation for First-in-Class Alzheimer’s Candidate
Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, recently…
Plasticell & GSK Sign Collaboration Agreement
Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem…
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates
AntriaBio, Inc. recently announced it is advancing the first development candidates from its oral plasma kallikrein inhibitor (PKI) portfolio. The two preclinical programs are AB402…
